A second-generation (F1) transgenic common marmoset line carrying an expanded-CAG ATXN3 transgene (spinocerebellar ataxia type 3, the most common polyglutamine disease) shows stable germline transmission but marked inter-animal variability: among five siblings, two developed early-onset rapidly progressive motor impairment, one developed late-onset mild impairment, and two remain asymptomatic, with phenotype severity tracking brain-region transgene expression levels rather than transgene integration-site count or copy number. The causes of this variability are unresolved: whether integration-site position effects, transgene dosage, or genetic-background modifiers (marmosets are not congenically bred) govern CNS transgene expression and phenotype severity; whether the asymptomatic carriers will develop disease and subclinical pathology with age; how transgene-driven neuronal dysfunction relates temporally to neurodegeneration; and whether phenotypes remain stable after meiotic segregation in F2 generations and single-locus carrier breeding. Resolving these determinants bears directly on colony expansion of the line to test its predictive validity (the ability to predict patient drug responses) as a preclinical platform for disease-modifying SCA3 therapies, for which phenotype consistency among animals is critical.

Background

Polyglutamine (polyQ) diseases are a family of autosomal-dominant neurodegenerative disorders, including Huntington's disease and the spinocerebellar ataxias, caused by CAG-repeat expansions in coding regions of unrelated genes that encode abnormally long polyglutamine tracts, leading to protein misfolding, aggregation, and progressive neuronal dysfunction and loss. Spinocerebellar ataxia type 3 (SCA3, also called Machado–Joseph disease), the most frequent SCA worldwide, is caused by a CAG expansion in ATXN3 and produces progressive ataxia with cerebellar Purkinje-cell loss, spinal-cord and brainstem neurodegeneration, and widespread intranuclear inclusions. Rodent models of SCA3 fail to reproduce the size, longevity, and complexity of the primate brain, which limits translational testing of candidate disease-modifying therapies such as antisense oligonucleotides and aggregation inhibitors, motivating genetically modified non-human primate (NHP) models. The first transgenic NHP polyQ model was the Huntington's-disease rhesus monkey (Yang et al. 2008), which exhibited CAG-repeat instability and marked inter-individual phenotypic variability, and germline transmission of transgenic HD monkeys was later demonstrated (Moran et al. 2015). The first transgenic marmoset model of SCA3 was generated by lentiviral transduction of embryos with a CMV-promoter construct encoding human ATXN3 with a 120-glutamine expansion plus a Venus reporter (a yellow-green fluorescent protein used to track transgene-expressing cells; Tomioka et al. 2017); its founders showed genetic mosaicism and multiple transgene integration sites, and founder phenotypic severity correlated with transgene expression in skin fibroblasts. Minakawa et al. (2025) then established the second generation: five offspring (PQD11–PQD15) of the symptomatic founder PQD1 all inherited the transgene with reduced numbers of integration sites (2–4 of the founder's 6), stable CAG-repeat length, and no mosaicism, giving improved construct validity (fidelity of the disease-causing mechanism to the human condition). Three siblings developed progressive motor impairment, scored longitudinally with the Marmoset Behavioral Assessment Scale (MBAS, a home-cage video rating of posture, activity, motility, muscle strength, and balance), segregating into early-onset/rapid (PQD13, PQD14) and late-onset/mild (PQD11) phenotypes, while PQD12 and PQD15 remained asymptomatic; post-mortem analysis of symptomatic animals revealed Purkinje-cell loss, spinal-cord neurodegeneration, and widespread intranuclear inclusions. Critically, motor severity correlated with transgene expression levels in disease-relevant CNS regions (cerebellum, spinal cord, striatum) but was discordant with integration-site number and transgene copy number (the mildest animal, PQD11, carried the most sites and copies), and even the two severe littermates with equivalent sites and copy number differed in region-specific expression. Because common marmosets (Callithrix jacchus) are maintained on outbred, non-congenic backgrounds (i.e., not bred to a genetically uniform strain, so individuals differ in background genotype), the authors could not distinguish integration-site position effects from genetic-background modifiers, and they inferred — from endpoint cross-sectional data — that transgene-driven neuronal dysfunction, rather than neuronal cell death itself, is the primary determinant of the behavioral phenotype, leaving its temporal evolution untested. To help clarify the causes of this variability, the source proposes whole-genome sequencing of all five second-generation marmosets combined with integration-site and transgene copy-number mapping, region-specific transgene-expression quantification, and standardized longitudinal phenotyping such as the MBAS. The model's ultimate value therefore hinges on three standard validation criteria for animal models — construct validity and face validity (phenotype similarity), already addressed, and predictive validity (ability to predict molecular and symptomatic drug responses in patients), which remains untested and, per consensus in the ataxia-model field, requires a stable, reproducibly phenotyped colony (Cendelin et al. 2022; Tuma et al. 2026).

Problem Statement

For the second-generation transgenic SCA3 marmoset line of Minakawa et al. (2025) — five F1 siblings (PQD11–PQD15) inheriting a lentiviral CMV-ATXN3-120Q-IRES-Venus transgene (human ATXN3 carrying 120 glutamine codons under a CMV promoter, linked via an internal ribosome entry site, IRES, to a Venus fluorescent-protein reporter) from the founder PQD1, with two early-onset/rapid, one late-onset/mild, and two asymptomatic phenotypes — determine the causes of the phenotypic variability among the animals, as the source paper frames them, in four jointly posed determinations: (1) identify whether integration-site position effects, transgene dosage, or additional genetic-background modifiers (marmosets being non-congenically bred) determine the observed inter-animal differences in CNS transgene expression and, through them, phenotype severity — noting that the published data are discordant with a simple copy-number explanation; (2) establish the natural history of the asymptomatic marmosets PQD12 and PQD15, i.e., whether they develop motor symptoms at a later age and whether their CNS shows subclinical pathology; (3) resolve how transgene-driven neuronal dysfunction and neurodegeneration relate over time, given that the current evidence for dysfunction preceding cell death is cross-sectional and endpoint-based; and (4) determine whether phenotypes remain stable and reproducible after meiotic segregation in F2 offspring, including breeding toward single-locus transgene carriers. These determinations bear on the model's stated end goal — colony expansion to test its predictive validity, i.e., its ability to predict molecular and symptomatic drug responses in SCA3 patients, with candidate disease-modifying interventions such as antisense oligonucleotides and aggregation inhibitors — for which the source notes that phenotype consistency among animals is critical.

References

  1. Minakawa EN, Owari K, Nogami N, Nakatani T, Koizumi M, Kawanobe A, Saga Y, Kudo M, Noguchi S, Hanakawa T, Hori Y, Numazawa H, Takeuchi T, Katakai Y, Saito R, Nagai Y, Saito Y, Tomioka I, Seki K. Establishment of a second-generation transgenic marmoset model of polyglutamine disease recapitulating neurological symptoms and pathology. bioRxiv preprint, posted 2025-03-13. DOI: 10.1101/2025.03.12.642922. https://doi.org/10.1101/2025.03.12.642922
  2. Minakawa EN, Owari K, Nogami N, Nakatani T, Koizumi M, Kawanobe A, Saga Y, Kudo M, Noguchi S, Hanakawa T, Hori Y, Numazawa H, Takeuchi T, Katakai Y, Saito R, Nagai Y, Saito Y, Tomioka I, Seki K. Establishment of a second-generation transgenic marmoset with germline transmission that models polyglutamine disease. Disease Models & Mechanisms 18(10):dmm052470 (2025). DOI: 10.1242/dmm.052470. https://doi.org/10.1242/dmm.052470
  3. Tomioka I, Ishibashi H, Minakawa EN, Motohashi HH, Takayama O, Saito Y, Popiel HA, Puentes S, Owari K, Nakatani T, Nogami N, Yamamoto K, Noguchi S, Yonekawa T, Tanaka Y, Fujita N, Suzuki H, Kikuchi H, Aizawa S, Nagano S, Yamada D, Nishino I, Ichinohe N, Wada K, Kohsaka S, Nagai Y, Seki K. Transgenic Monkey Model of the Polyglutamine Diseases Recapitulating Progressive Neurological Symptoms. eNeuro 4(2):ENEURO.0250-16.2017 (2017). DOI: 10.1523/ENEURO.0250-16.2017. https://doi.org/10.1523/ENEURO.0250-16.2017
  4. Tomioka I, Nagai Y, Seki K. Generation of Common Marmoset Model Lines of Spinocerebellar Ataxia Type 3. Frontiers in Neuroscience 14:548002 (2020). DOI: 10.3389/fnins.2020.548002. https://doi.org/10.3389/fnins.2020.548002
  5. Yang S-H, Cheng P-H, Banta H, Piotrowska-Nitsche K, Yang J-J, Cheng ECH, Snyder B, Larkin K, Liu J, Orkin J, Fang Z-H, Smith Y, Bachevalier J, Zola SM, Li S-H, Li X-J, Chan AWS. Towards a transgenic model of Huntington's disease in a non-human primate. Nature 453(7197):921-924 (2008). DOI: 10.1038/nature06975. https://doi.org/10.1038/nature06975
  6. Moran S, Chi T, Prucha MS, Ahn KY, Connor-Stroud F, Jean S, Gould K, Chan AWS. Germline transmission in transgenic Huntington's disease monkeys. Theriogenology 84(2):277-285 (2015). DOI: 10.1016/j.theriogenology.2015.03.016. https://doi.org/10.1016/j.theriogenology.2015.03.016
  7. Cendelin J, Cvetanovic M, Gandelman M, Hirai H, Orr HT, Pulst SM, Strupp M, Tichanek F, Tuma J, Manto M. Consensus Paper: Strengths and Weaknesses of Animal Models of Spinocerebellar Ataxias and Their Clinical Implications. The Cerebellum 21(3):452-481 (2022). DOI: 10.1007/s12311-021-01311-1. https://doi.org/10.1007/s12311-021-01311-1
  8. Tuma J, Cendelin J, Kapl S. Animal Models of Neurodegenerative Diseases. In: Models of Neurodegenerative Diseases (Contemporary Clinical Neuroscience series), Springer, Cham, pp. 63-135 (2026). DOI: 10.1007/978-3-032-18296-8_4. https://doi.org/10.1007/978-3-032-18296-8_4